The Rare Diseases Finance Partner is a newly created role, vital for the financial running of the Rare Diseases business. This role reports into the Group Finance Director and partners with the President of Rare Diseases, as well as the R&D and Commercial teams. The Rare Diseases division currently has one lead asset, Hu14.18K322A (Hu14.18), an immunotherapy currently in Phase IIb/III clinical development for the treatment of high-risk neuroblastoma. This asset was acquired through as part of the acquisition of Renaissance Pharma by EP Group. If you are keen to join a patient centric, high-growth company, then read on and apply today!

What You Will Do

Finance Partner responsibilities

• Responsible for full financial tracking of spend within Renaissance Pharma Ltd
• Proactively support business in managing their budget, making recommendations and finding solutions to manage spend as business activities and priorities change